HomeN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Nakaraang pagsara
R$37.36
Sakop ng taon
R$25.64 - R$44.95
Market cap
14.40B USD
Average na Volume
102.00
P/E ratio
-
Dividend yield
-
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 687.50M | 16.49% |
Gastos sa pagpapatakbo | 286.30M | 18.31% |
Net na kita | 107.50M | 65.38% |
Net profit margin | 15.64 | 42.05% |
Kita sa bawat share | 1.65 | 1.23% |
EBITDA | 152.90M | -1.48% |
Aktuwal na % ng binabayarang buwis | 32.60% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 975.60M | -6.09% |
Kabuuang asset | 3.89B | 17.69% |
Kabuuang sagutin | 1.20B | 50.23% |
Kabuuang equity | 2.69B | — |
Natitirang share | 99.18M | — |
Presyo para makapag-book | 1.37 | — |
Return on assets | 9.61% | — |
Return on capital | 11.72% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 107.50M | 65.38% |
Cash mula sa mga operasyon | 102.00M | 57.89% |
Cash mula sa pag-invest | -29.00M | -2.84% |
Cash mula sa financing | -3.30M | 98.87% |
Net change in cash | 69.90M | 127.24% |
Malayang cash flow | 25.20M | 126.07% |
Tungkol
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Itinatag
1992
Headquarters
Website
Mga Empleyado
1,800
